Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Immune Checkpoint TherapyRadiotherapyMetastatic Gastric Carcinoma
Interventions
COMBINATION_PRODUCT

Node-Sparing Radiotherapy plus first-line therapy

Patients will receive node-sparing modified short-course radiotherapy, followed by standard first-line chemotherapy combined with a PD-1 inhibitor starting 2-5 days after radiotherapy. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.

COMBINATION_PRODUCT

First-line treatment

Patients will receive standard first-line chemotherapy combined with a PD-1 inhibitor. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.

Trial Locations (1)

510655

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER